The Johnson and Johnson Vision Solution for meibomian gland dysfunction (MGD) allows eye care professionals to effectively identify and treat MGD.
With 86 per cent of all dry eye being attributed to MGD, and 300 million dry eye sufferers worldwide, MGD patients represent one of the largest patient segments within eye care practices. MGD is prevalent, chronic, and progressive. By treating the root cause, eye care professionals intervene in the progression of the disease, improve gland function, and alleviate dry eye symptoms.
Contact: Johnson and Johnson Account Manager
